Zacks Research Has Positive Forecast for Cencora Q3 Earnings

Cencora, Inc. (NYSE:COR) – Stock analysts at Zacks Research increased their Q3 2025 earnings per share estimates for shares of Cencora in a report released on Wednesday, February 26th. Zacks Research analyst I. Bandyopadhyay now anticipates that the company will earn $3.74 per share for the quarter, up from their previous forecast of $3.57. The consensus estimate for Cencora’s current full-year earnings is $15.37 per share. Zacks Research also issued estimates for Cencora’s Q1 2026 earnings at $3.93 EPS, Q2 2026 earnings at $4.45 EPS, FY2026 earnings at $16.65 EPS, Q1 2027 earnings at $4.21 EPS and FY2027 earnings at $18.07 EPS.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%.

A number of other research analysts have also commented on COR. JPMorgan Chase & Co. increased their price objective on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Wells Fargo & Company increased their price objective on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a report on Wednesday, January 29th. Evercore ISI increased their price objective on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Robert W. Baird increased their price objective on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Finally, UBS Group increased their price objective on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $277.90.

Cencora Stock Performance

Shares of NYSE COR opened at $253.49 on Friday. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The firm has a market cap of $49.16 billion, a price-to-earnings ratio of 36.06, a P/E/G ratio of 1.31 and a beta of 0.49. The business’s 50-day simple moving average is $241.19 and its 200-day simple moving average is $237.73. Cencora has a 52 week low of $214.77 and a 52 week high of $262.26.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date is Friday, February 14th. Cencora’s dividend payout ratio (DPR) is currently 31.29%.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the sale, the executive vice president now owns 15,374 shares of the company’s stock, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 10.80% of the company’s stock.

Institutional Trading of Cencora

A number of hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its position in shares of Cencora by 0.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,859,452 shares of the company’s stock worth $1,990,542,000 after acquiring an additional 78,066 shares during the period. State Street Corp lifted its position in shares of Cencora by 3.8% in the 3rd quarter. State Street Corp now owns 8,045,896 shares of the company’s stock worth $1,810,970,000 after acquiring an additional 291,867 shares during the period. Bank of America Corp DE lifted its position in shares of Cencora by 62.3% in the 4th quarter. Bank of America Corp DE now owns 5,193,807 shares of the company’s stock worth $1,166,944,000 after acquiring an additional 1,994,256 shares during the period. Wellington Management Group LLP lifted its position in shares of Cencora by 7.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company’s stock worth $1,168,927,000 after acquiring an additional 338,452 shares during the period. Finally, Boston Partners lifted its position in shares of Cencora by 2.6% in the 4th quarter. Boston Partners now owns 5,007,100 shares of the company’s stock worth $1,128,058,000 after acquiring an additional 125,611 shares during the period. Institutional investors own 97.52% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.